Hepatic Intervention Strategies for Colorectal Liver Metastases

Colorectal liver metastases represent a major therapeutic challenge, affecting up to a third of patients with colorectal cancer and accounting for the principal cause of disease-related mortality. Surgical resection remains the only potentially curative option, with advances in parenchymal-sparing techniques and intraoperative ultrasound facilitating complete removal of metastatic deposits. For small or deep lesions unsuitable for resection, image-guided ablative modalities such as radiofrequency and microwave ablation have gained acceptance. Conversion chemotherapy regimens, combining fluoropyrimidines with oxaliplatin or irinotecan and often supplemented by anti-VEGF or anti-EGFR agents, can downsize initially unresectable metastases to enable secondary resection. Locoregional therapies—transarterial chemoembolisation and radioembolisation—provide hepatic control in patients unfit for surgery or after progression on systemic treatment. Underpinning these strategies is an appreciation of tumour heterogeneity in the liver, notably histopathological growth patterns: desmoplastic metastases induce angiogenesis within a fibrotic rim, while replacement lesions spread via vessel co-option. The dynamic interaction between tumour invasion and the host’s reparative response, exemplified by the formation of a perimetastatic capsule, shapes prognosis and suggests novel therapeutic targets. Optimal management demands a multidisciplinary approach that integrates surgical, systemic and locoregional modalities in accordance with individual metastatic biology and patient fitness.

Research from Nature Portfolio

Systematic analysis of colorectal liver metastases has revealed that the extent and composition of a perimetastatic capsule strongly influence patient survival. Detailed quantification in a large patient cohort identified a zonated stroma, transitioning from a benign NGFR-rich layer at the liver interface to a FAP-rich layer towards the tumour, with greater encapsulation correlating with reduced tumour viability. Preoperative chemotherapy and experimental tumour ablation in murine models both induced capsule formation, supporting a reparative, rather than tumour-driven, origin. These insights have led to a proposed model whereby efficient tumour colonisation and a reparative liver-injury reaction act as opposing determinants of metastatic aggressiveness, highlighting the capsule as a possible biomarker and therapeutic target.

Hepatic Intervention Strategies for Colorectal Liver Metastases publication trend

The graph below shows the total number of articles in hepatic intervention strategies for colorectal liver metastases across all publications each year (not limited to Nature Index journals).

Technical terms

Histopathological growth patterns (HGPs): Classification of the tumour–liver interface as desmoplastic (fibrotic rim with angiogenesis) or replacement (direct tumour–hepatocyte contact via vessel co-option).

Vessel co-option (VCO): Process by which metastatic cells exploit existing liver vasculature instead of inducing new blood vessel formation.

Desmoplastic stroma: Fibrous tissue surrounding a metastasis, characterised by activated fibroblasts and new vessel growth, often linked to better prognosis.

Perimetastatic capsule: Layer of zonated reparative stroma that develops at the tumour–liver boundary, modulating tumour viability and patient survival.

Perfusion fraction (fp): Parameter derived from diffusion-weighted imaging that reflects the microvascular blood flow component within a lesion and may serve as an early marker of response to anti-angiogenic therapy.

References

1. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution. Molecular Cancer (2023).
2. An idiosyncratic zonated stroma encapsulates desmoplastic liver metastases and originates from injured liver. Nature Communications (2023).
3. The histological growth patterns in liver metastases from colorectal cancer display differences in lymphoid, myeloid, and mesenchymal cells. MedComm (2024).
4. Multidisciplinary approach of liver metastases from colorectal cancer. Annals of Gastroenterological Surgery (2019).
5. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis (2019).
6. Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging. PLOS ONE (2015).
7. Liver-First Approach for Synchronous Colorectal Metastases: Analysis of 7360 Patients from the LiverMetSurvey Registry. Annals of Surgical Oncology (2021).